Drug Trial Radar · NCT03108495
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
210
Actual
Start
Jun 22, 2017
Primary completion
Aug 22, 2025
Study completion Aug 22, 2025
Sponsor
- Lead sponsor
- Iovance Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by IL-2 after a non-myeloablative lymphodepletion (NMA-LD) preparative regimen for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma.
Conditions
- Cervical Carcinoma
Interventions
LN-145Biological
A tumor sample is resected from each participant and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
LN-145 + pembrolizumabBiological
A tumor sample is resected from each participant and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1 and 2: Objective Response RateTime frame: Up to 60 months
- Cohort 3: Number of Participants With Adverse EventsTime frame: Up to 60 months
- Cohort 4: Number of Participants With Adverse EventsTime frame: Up to 60 months
- Cohort 4: Efficacy/Objective Response RateTime frame: Up to 60 months
- Cohort 5: Number of Participants With Adverse EventsTime frame: Up to 60 months
- Cohort 5: Efficacy/Objective Response RateTime frame: Up to 60 months
Locations
43 sites in 8 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center Center For Women's Health
Phoenix, Arizona
University of Southern California
Los Angeles, California
University of California San Diego
San Diego, California
Sylvester Comprehensive Cancer Center
Miami, Florida
University of Florida Health Cancer Center
Orlando, Florida
University of South Florida H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Augusta University
Augusta, Georgia
University of Chicago
Chicago, Illinois
James Graham Brown Cancer Center
Louisville, Kentucky
LSU Health Sciences Center
New Orleans, Louisiana
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Rutgers University
Newark, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Allegheny Health
Pittsburgh, Pennsylvania
UPMC Cancer Center
Pittsburgh, Pennsylvania
Avera Medical Group Oncology
Sioux Falls, South Dakota
MD Anderson Cancer Center
Houston, Texas
University of Virginia
Charlottesville, Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Centre Léon Bérard
Lyon, France
Gustave Roussy Cancer Campus
Villejuif, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, Auvergne-Rhône-Alpes, France
Universitätsklinikum Erlangen
Erlangen, Bavaria, Germany
Universitätsklinikum Carl Gustav Carus
Dresden, Saxony, Germany
Istituto Europeo di Oncologia
Miano, Milano, Italy
Academisch Medisch Centrum
Amsterdam, AZ, Netherlands
Hospital Universitari Vall d'Hebrón
Barcelona, Spain
Institut Català d'Oncologia
Barcelona, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Hospital Universitario Madrid Sanchinarro
Madrid, Spain
Clínica Universidad de Navarra
Pamplona, Navarre, Spain
Inselspital
Bern, Switzerland
Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie
Lausanne, Switzerland
Guy's & St.Thomas NHS Foundation Trust
London, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.